Logo

Gilead Reports Results of Biktarvy (Bictegravir- Emtricitabine- Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1

Share this

Gilead Reports Results of Biktarvy (Bictegravir- Emtricitabine- Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1

Shots:

  • The P-III 1490 Study involves assessing of Biktarvy (BIC 50/FTC 200/TAF 25mg tablets) vs dolutegravir and emtricitabine/tenofovir alafenamide (50 mg) (DTG+FTC/TAF) in ratio (1:1) patients with HIV-1 naive to HIV therapy in adults for 96 wks.
  • P-III Study 1490 results: HIV-1 RNA levels less than 50 copies/mL 95%; well-tolerated with low discontinuations @48 wks. & 96wks. (1%- 2% vs 4%- 2%) presented at HIV Glasgow 2018. The ongoing 1490 trial will continue for 144 wks.
  • Biktarvy includes a boxed warning regarding its discontinuation in the US product label for risk of severe acute exacerbations of hepatitis B in patients with HIV-1 and HBV and is available in Australia- Canada- EU- Hong Kong and the US

Ref: Gilead| Image: Gilead


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions